CAR T-Cell Immunotherapy for ALL – National Cancer Institute
Posted: October 27, 2015 at 6:42 pm
On This Page
For years, the cornerstones of cancer treatment have been surgery, chemotherapy, and radiation therapy. Over the last decade, targeted therapies like imatinib (Gleevec) and trastuzumab (Herceptin)drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cellshave also emerged as standard treatments for a number of cancers.
Illustration of the components of second- and third-generation chimeric antigen receptor T cells. (Adapted by permission from the American Association for Cancer Research: Lee, DW et al. The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer. Clin Cancer Res; 2012;18(10); 278090. doi:10.1158/1078-0432.CCR-11-1920)
And now, despite years of starts and stutter steps, excitement is growing for immunotherapytherapies that harness the power of a patients immune system to combat their disease, or what some in the research community are calling the fifth pillar of cancer treatment.
One approach to immunotherapy involves engineering patients own immune cells to recognize and attack their tumors. And although this approach, called adoptive cell transfer (ACT), has been restricted to small clinical trials so far, treatments using these engineered immune cells have generated some remarkable responses in patients with advanced cancer.
For example, in several early-stage trials testing ACT in patients with advanced acute lymphoblastic leukemia (ALL) who had few if any remaining treatment options, many patients cancers have disappeared entirely. Several of these patients have remained cancer free for extended periods.
Equally promising results have been reported in several small trials involving patients with lymphoma.
These are small clinical trials, their lead investigators cautioned, and much more research is needed.
But the results from the trials performed thus far are proof of principle that we can successfully alter patients T cells so that they attack their cancer cells, said one of the trial's leaders, Renier J. Brentjens, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center (MSKCC) in New York.
Adoptive cell transfer is like giving patients a living drug, continued Dr. Brentjens.
Thats because ACTs building blocks are T cells, a type of immune cell collected from the patients own blood. After collection, the T cells are genetically engineered to produce special receptors on their surface called chimeric antigen receptors (CARs). CARs are proteins that allow the T cells to recognize a specific protein (antigen) on tumor cells. These engineered CAR T cells are then grown in the laboratory until they number in the billions.
The expanded population of CAR T cells is then infused into the patient. After the infusion, if all goes as planned, the T cells multiply in the patients body and, with guidance from their engineered receptor, recognize and kill cancer cells that harbor the antigen on their surfaces.
Although adoptive cell transfer has been restricted to small clinical trials so far, treatments using these engineered immune cells have generated some remarkable responses in patients with advanced cancer.
This process builds on a similar form of ACT pioneered by Steven Rosenberg, M.D., Ph.D., and his colleagues from NCIs Surgery Branch for patients with advanced melanoma.
The CAR T cells are much more potent than anything we can achieve with other immune-based treatments being studied, said Crystal Mackall, M.D., of NCIs Pediatric Oncology Branch (POB).
Even so, investigators working in this field caution that there is still much to learn about CAR T-cell therapy. But the early results from trials like these have generated considerable optimism.
CAR T-cell therapy eventually may become a standard therapy for some B-cell malignancies like ALL and chronic lymphocytic leukemia, Dr. Rosenberg wrote in a Nature Reviews Clinical Oncology article.
More than 80 percent of children who are diagnosed with ALL that arises in B cellsthe predominant type of pediatric ALLwill be cured by intensive chemotherapy.
For patients whose cancers return after intensive chemotherapy or a stem cell transplant, the remaining treatment options are close to none, said Stephan Grupp, M.D., Ph.D., of the Childrens Hospital of Philadelphia (CHOP) and the lead investigator of a trial testing CAR T cells primarily in children with ALL. This treatment may represent a much-needed new option for such patients, he said.
Trials of CAR T cells in adults and children with leukemia and lymphoma have used T cells engineered to target the CD19 antigen, which is present on the surface of nearly all B cells, both normal and cancerous.
In the CHOP trial, which is being conducted in collaboration with researchers from the University of Pennsylvania, all signs of cancer disappeared (a complete response) in 27 of the 30 patients treated in the study, according to findings published October 16 in the New England Journal of Medicine.
Nineteen of the 27 patients with complete responses have remained in remission, the study authors reported, with 15 of these patients receiving no further therapy and 4 patients withdrawing from the trial to receive other therapy.
According to the most recent data from a POB trial that included children with ALL, 14 of 20 patients had a complete response. And of the 12 patients who had no evidence of leukemic cells, called blasts, in their bone marrow after CAR T-cell treatment, 10 have gone on to receive a stem cell transplant and remain cancer free, reported the studys lead investigator, Daniel W. Lee, M.D., also of the POB.
Dr. Crystal Mackall
Our findings strongly suggest that CAR T-cell therapy is a useful bridge to bone marrow transplant for patients who are no longer responding to chemotherapy, Dr. Lee said.
Similar results have been seen in phase I trials of adult patients conducted at MSKCC and NCI.
In findings published in February 2014, 14 of the 16 participants in the MSKCC trial treated to that point had experienced complete responses, which in some cases occurred 2 weeks or sooner after treatment began. Of those patients who were eligible, 7 underwent a stem cell transplant and are still cancer free.
The NCI-led trial of CAR T cells included 15 adult patients, the majority of whom had advanced diffuse large B-cell lymphoma. Most patients in the trial had either complete or partial responses, reported James Kochenderfer, M.D., and his NCI colleagues.
Our data provide the first true glimpse of the potential of this approach in patients with aggressive lymphomas that, until this point, were virtually untreatable, Dr. Kochenderfer said. [NCI Surgery Branch researchers have also reported promising results from one of the first trials testing CAR T cells derived from donors, rather than the patients themselves, to treat leukemia and lymphoma.]
Other findings from the trials have been encouraging, as well. For example, the number of CAR T cells increased dramatically after infusion into patients, as much as 1,000-fold in some individuals. In addition, after infusion, CAR T cells were detected in the central nervous system, a so-called sanctuary site where solitary cancer cells that have evaded chemotherapy or radiation may hide. In two patients in the NCI pediatric trial, the CAR T-cell treatment eradicated cancer that had spread to the central nervous system.
If CAR T cells can persist at these sites, it could help fend off relapses, Dr. Mackall noted.
CAR T-cell therapy can cause several worrisome side effects, perhaps the most troublesome being cytokine-release syndrome.
The infused T cells release cytokines, which are chemical messengers that help the T cells carry out their duties. With cytokine-release syndrome, there is a rapid and massive release of cytokines into the bloodstream, which can lead to dangerously high fevers and precipitous drops in blood pressure.
Cytokine-release syndrome is a common problem in patients treated with CAR T cells. In the POB and CHOP trials, patients with the most extensive disease prior to receiving the CAR T cells were more likely to experience severe cases of cytokine-release syndrome.
For most patients, trial investigators have reported, the side effects are mild enough that they can be managed with standard supportive therapies, including steroids.
The research team at CHOP noticed that patients experiencing severe reactions all had particularly high levels of IL-6, a cytokine that is secreted by T cells and macrophages in response to inflammation. So they turned to two drugs that are approved to treat inflammatory conditions like juvenile arthritis: etanercept (Enbrel) and tocilizumab (Actemra), the latter of which blocks IL-6 activity.
The patients had excellent responses to the treatment, Dr. Grupp said. We believe that [these drugs] will be a major part of toxicity management for these patients.
The other two teams subsequently used tocilizumab in several patients. Dr. Brentjens agreed that both drugs could become a useful way to help manage cytokine-release syndrome because, unlike steroids, they dont appear to affect the infused CAR T cells activity or proliferation.
Even with these encouraging preliminary findings, more research is needed before CAR T-cell therapy becomes a routine option for patients with ALL.
We need to treat more patients and have longer follow-up to really say what the impact of this therapy is [and] to understand its true performance characteristics, Dr. Grupp said.
We need to treat more patients and have longer follow-up to really say what the impact of this therapy is [and] to understand its true performance characteristics.
Dr. Stephan Grupp
Several other trials testing CAR T cells in children and adults are ongoing and, with greater interest and involvement from the pharmaceutical and biotechnology sector, more trials testing CAR T cells are being planned.
Researchers are also studying ways to improve on the positive results obtained to date, including refining the process by which the CAR T cells are produced.
Research groups like Dr. Brentjens are also working to make a superior CAR T cell, including developing a better receptor and identifying better targets.
For example, Dr. Lee and his colleagues at NCI have developed CAR T cells that target the CD22 antigen, which is also present on most B cells, although in smaller quantities than CD19. The CD22-targeted T cells, he believes, could be used in concert with CD19-targeted T cells as a one-two punch in ALL and other B-cell cancers. NCI researchers hope to begin the first clinical trial testing the CD22-targeted CAR T cells in November 2014.
Based on the success thus far, several research groups across the country are turning their attention to developing engineered T cells for other cancers, including solid tumorslike pancreatic and brain cancers.
The stage has now been set for greater progress, Dr. Lee believes.
NCI investigators, for example, now have a platform to plug and play better CARs into that system, without a lot of additional R&D time, he continued. Everything else should now come more rapidly.
The rest is here:
CAR T-Cell Immunotherapy for ALL - National Cancer Institute
- Gene Therapy and Cell Therapy Defined | ASGCT - American ... - October 20th, 2015
- StemCell Therapy MD - October 3rd, 2015
- Stem Cell Therapy in Mexico - May 8th, 2015
- Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients - Video - May 1st, 2015
- Platelet Rich Plasma Injections For Chronic Pain Relief May Help You Avoid Sugery - Video - May 1st, 2015
- Stem Cell Treatment for COPD | StemRx Bioscience Solutions - Video - April 25th, 2015
- Stem Cell Therapy Market in Asia-Pacific to 2018 - Video - April 22nd, 2015
- Phytoscience Philipine celebrity Share good effect of stem cell Therapy - Video - April 18th, 2015
- STEM CELL therapy incredible results for severe MS - Video - April 18th, 2015
- Clinical Benefits of Stem Cell Therapy - Video - April 18th, 2015
- NYC Health & Longevity Center Now Offering Stem Cell Therapy to Avoid Joint Replacement - April 13th, 2015
- U.S. Stem Cell Clinic: What Conditions Can Be Treated? - Video - April 12th, 2015
- Stem Cell Therapy In USA - April 12th, 2015
- Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video - April 11th, 2015
- What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How long will my recovery take? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: Stem Cell Banking - Video - April 11th, 2015
- U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: When should I expect to see results? - Video - April 11th, 2015
- Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video - April 3rd, 2015
- Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016 - April 3rd, 2015
- Stem Cell Therapy for Neuromuscular Diseases | InTechOpen - March 31st, 2015
- Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy to Help Patients Avoid Hip and Knee Replacement - March 31st, 2015
- Center of Regenerative Orthopedics in South Florida Now Offering Stem Cell Therapy to Help Avoid Hip and Knee ... - March 31st, 2015
- Ask Dr. Lemper | Stem Cell Therapy Treatments - Video - March 29th, 2015
- No stem cell treatment for public servant's dodgy knee - March 26th, 2015
- Stem Cell Therapy - Lilli Donovan - Video - March 25th, 2015
- Stem Cell Research - Stem Cell Treatments - Treatments ... - March 25th, 2015
- What is "Stem cell therapy" ? | Steps in PRP Treatment : TV5 News - Video - March 23rd, 2015
- Stem cell clinics under govt scanner - March 22nd, 2015
- SuperCells at Centre for Life - Video - March 21st, 2015
- Knee arthritis 3 years after stem cell therapy by Harry Adelson, N.D. - Video - March 21st, 2015
- Stem Cell Injection Treatment Stem Cell Therapy - Video - March 21st, 2015
- stem cell therapy di indonesia Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video - March 20th, 2015
- Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video - March 20th, 2015
- Stem cell therapy may help treat type 2 diabetes - March 20th, 2015
- CAR T-Cell Therapy - Nebraska Medicine - Video - March 18th, 2015
- Stem Cell Therapy- Sci Video2 - Video - March 18th, 2015
- Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics - March 17th, 2015
- Stem Cell Research & Therapy | Full text | Amnion-derived ... - March 15th, 2015
- High-Dose Immunosuppressive Therapy and Autologous ... - March 15th, 2015
- Miracle stem cell therapy reverses multiple sclerosis - Video - March 14th, 2015
- Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video - March 13th, 2015
- Stem Cell Therapy Network - Video - March 12th, 2015
- Stem Cell Therapy Cream - Video - March 9th, 2015
- BioLogic Stem Cell Therapy Cream - Video - March 8th, 2015
- World Over - 2015-02-26 - Vatican latest, ISIS, stem cell therapy, Ray Flynn with Raymond Arroyo - Video - March 8th, 2015
- Shoulder Labral Tear Repair Using Stem Cell Therapy - Orthopedic Surgeon, Dr. Wade McKenna - Video - March 6th, 2015
- What Makes Riordan-McKenna Institute Different? Stem Cell Therapy for Orthopedics - Video - March 6th, 2015
- Overcoming Knee Replacement Surgery Faster Using Amniotic Tissue-Enhanced Stem Cell Therapy - Video - March 6th, 2015
- Stem Cell Therapy in Osteo Arthritis Knee - Video - March 6th, 2015
- stem cell therapy helps avoiding knee surgery - Video - March 6th, 2015
- Stem cell therapy in AKI Dr Mohamed Kamal - Video - March 6th, 2015
- Stem Cell Therapy for Bone Fractures - Board-Certified Orhopedic Surgeon, Wade McKenna DO - Video - March 5th, 2015
- Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video - March 1st, 2015
- Animal cells for a younger you - March 1st, 2015
- 'Miracle' stem cell therapy reverses multiple sclerosis - March 1st, 2015
- Stem cell therapy a boon to Parkinson's patients - February 27th, 2015
- Stem Cell Research & Therapy | Full text | Aromatic ... - February 23rd, 2015
- Why Stem Cell Therapy? - Video - February 22nd, 2015
- What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? - Video - February 21st, 2015
- Dr Ellis hosts seminar on Stem Cell Therapy & Facial Rejuvenation - Video - February 17th, 2015
- Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D. - Video - February 16th, 2015
- How about Stem Cell Therapy for LBD, Nova Cells Institute stem cells - Video - February 14th, 2015
- Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital - Video - February 14th, 2015
- Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? - February 10th, 2015
- International Stem Cell completes cell bank manufacturing for Parkinson's disease clinical trial - February 4th, 2015
- Tampa stem cell clinic is long on promises, not evidence - February 1st, 2015
- Denver Regenerative Medicine - What is regenerative medicine? - Video - January 30th, 2015
- Cell Trials - January 26th, 2015
- "She's Happy" RMG's next Stem Cell Miracle - Video - January 21st, 2015
- Nutech Mediworld - Pioneering human embryonic stem cell therapy - Video - January 21st, 2015
- Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video - January 20th, 2015
- Dr Sherif Stem cell therapy on OA - Video - January 18th, 2015
- Live100 Hospitals - Stem Cell Therapy - Video - January 16th, 2015
- How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video - January 16th, 2015